Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH
Authors' conclusion
In this subgroup analysis of SURPASS-SWITCH, switching to tirzepatide from dulaglutide was generally well-tolerated and associated with significant and consistent improvements in HbA1c and weight reductions versus dulaglutide across all baseline subgroups evaluated. These results indicate that switching to tirzepatide may provide a clinical option across a range of baseline characteristics when treatment goals are not being met with dulaglutide.
Study context
- Population
- Adults with T2D, hemoglobin A1c (HbA1c) ≥7.0% to ≤9.5%, on stable dulaglutide ≥6 months, stable 0–3 oral antihyperglycemic medications ≥3 months, stable body weight, body mass index (BMI) ≥25 kg/m²randomized 1:1
- Comparison
- Switch to tirzepatide vs continued dulaglutide
- Primary endpoint
- Changes from baseline in HbA1c and body weight in prespecified baseline subgroups (age, HbA1c, T2D duration, dulaglutide dose and duration, BMI, ethnicity, sex)
- Follow-up
- Week 40
Methodological detailsprespecified subgroup analysis, phase IV, open-label, active-controlled, parallel-group, multicenter, multinational
- Prespecified subgroup analysis
- Phase IV
- Open-label
- Active-controlled
- Parallel-group
- Multicenter
- Multinational
Primary result
As reported in the abstract
- Reductions in HbA1c and body weight significant and consistently greater with tirzepatide across all prespecified baseline subgroups
- HbA1c reduction greater in subgroups with higher baseline HbA1c and low baseline BMI
- Weight reduction greater in the non-Hispanic or non-Latino subgroup
Safety
- Safety profile similar across subgroups
- Nausea and diarrhea usually the most frequently reported treatment-emergent AEs in each subgroup
Original publication
Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH. BMJ Open Diabetes Res Care. Published 30 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →